Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
258.04
+23.63 (10.08%)
May 13, 2025, 9:38 AM - Market open
Bio-Rad Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,541 | 2,567 | 2,671 | 2,802 | 2,923 | 2,546 | Upgrade
|
| Revenue Growth (YoY) | -2.46% | -3.92% | -4.67% | -4.12% | 14.81% | 10.12% | Upgrade
|
| Cost of Revenue | 1,178 | 1,188 | 1,244 | 1,235 | 1,259 | 1,108 | Upgrade
|
| Gross Profit | 1,363 | 1,379 | 1,427 | 1,567 | 1,663 | 1,438 | Upgrade
|
| Selling, General & Admin | 797 | 814 | 841.7 | 827.8 | 851.02 | 798.8 | Upgrade
|
| Research & Development | 291.9 | 295.9 | 247.4 | 256.9 | 247.34 | 217.76 | Upgrade
|
| Operating Expenses | 1,089 | 1,110 | 1,089 | 1,085 | 1,098 | 1,017 | Upgrade
|
| Operating Income | 274.2 | 269 | 337.8 | 482.6 | 564.74 | 421.33 | Upgrade
|
| Interest Expense | -48.6 | -48.9 | -49.4 | -38.1 | -1.55 | -21.86 | Upgrade
|
| Interest & Investment Income | 84.2 | 82 | 100.9 | 58.1 | 18.9 | 18.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.6 | 3.9 | 7.3 | 0.2 | -2.75 | -1.77 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.3 | 1.6 | 4.9 | -5.2 | 0.68 | -1.81 | Upgrade
|
| EBT Excluding Unusual Items | 315.7 | 307.6 | 401.5 | 497.6 | 580.01 | 414.08 | Upgrade
|
| Merger & Restructuring Charges | -26.1 | - | - | - | -64.4 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -3,040 | -2,650 | -1,252 | -5,203 | 4,933 | 4,492 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1.4 | - | 11.7 | Upgrade
|
| Pretax Income | -2,750 | -2,343 | -850.1 | -4,704 | 5,449 | 4,918 | Upgrade
|
| Income Tax Expense | -586.1 | -498.3 | -212.8 | -1,077 | 1,195 | 1,104 | Upgrade
|
| Net Income | -2,164 | -1,844 | -637.3 | -3,628 | 4,254 | 3,814 | Upgrade
|
| Net Income to Common | -2,164 | -1,844 | -637.3 | -3,628 | 4,254 | 3,814 | Upgrade
|
| Net Income Growth | - | - | - | - | 11.54% | 116.88% | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 29 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 29 | 30 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | -3.00% | -3.41% | -1.93% | -1.40% | 0.16% | -0.08% | Upgrade
|
| EPS (Basic) | -77.10 | -65.36 | -21.82 | -121.79 | 142.61 | 128.13 | Upgrade
|
| EPS (Diluted) | -77.10 | -65.36 | -21.82 | -121.79 | 140.83 | 126.47 | Upgrade
|
| EPS Growth | - | - | - | - | 11.35% | 117.04% | Upgrade
|
| Free Cash Flow | 355.5 | 289.6 | 218.2 | 81.6 | 535.75 | 476.44 | Upgrade
|
| Free Cash Flow Per Share | 12.66 | 10.26 | 7.47 | 2.74 | 17.74 | 15.80 | Upgrade
|
| Gross Margin | 53.64% | 53.73% | 53.42% | 55.93% | 56.91% | 56.48% | Upgrade
|
| Operating Margin | 10.79% | 10.48% | 12.65% | 17.22% | 19.32% | 16.55% | Upgrade
|
| Profit Margin | -85.16% | -71.86% | -23.86% | -129.45% | 145.57% | 149.84% | Upgrade
|
| Free Cash Flow Margin | 13.99% | 11.28% | 8.17% | 2.91% | 18.33% | 18.72% | Upgrade
|
| EBITDA | 426.8 | 420.6 | 483.7 | 619.9 | 702.34 | 559.93 | Upgrade
|
| EBITDA Margin | 16.80% | 16.39% | 18.11% | 22.12% | 24.03% | 22.00% | Upgrade
|
| D&A For EBITDA | 152.6 | 151.6 | 145.9 | 137.3 | 137.6 | 138.6 | Upgrade
|
| EBIT | 274.2 | 269 | 337.8 | 482.6 | 564.74 | 421.33 | Upgrade
|
| EBIT Margin | 10.79% | 10.48% | 12.65% | 17.22% | 19.32% | 16.55% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 21.93% | 22.44% | Upgrade
|
Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.